New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
04:55 EDTPFE, PFE, VRTX, VRTX, BAYRY, BAYRY, CBST, CBST, IRWD, IRWD, AMGN, AMGN, SHPG, SHPG, GSK, GSK, CELG, CELG, BMY, BMY, LLY, LLYQ1 Productions to hold a conference
Customer Centric Medical Information Conference to be held in Boston on June 26-27.
News For PFE;BMY;CELG;GSK;SHPG;AMGN;IRWD;CBST;BAYRY;VRTX;LLY From The Last 14 Days
Check below for free stories on PFE;BMY;CELG;GSK;SHPG;AMGN;IRWD;CBST;BAYRY;VRTX;LLY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 4, 2014
16:05 EDTPFEPfizer granted orphan status for sickle cell disease drug
Subscribe for More Information
10:29 EDTIRWDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:13 EDTIRWDIronwood downgraded at Cowen
Subscribe for More Information
08:11 EDTLLYEli Lilly's insulin peglispro for diabetes shows positive Phase III results
Subscribe for More Information
08:02 EDTBMYTeva launches generic Baraclude in U.S.
Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).
07:33 EDTCELGCelgene announces REVLIMID Phase III FIRST trial met primary endpoint
Subscribe for More Information
07:23 EDTPFEAstraZeneca called for inversion clamp down as part of defense, WSJ says
Amid its defense against an unsolicited takeover bid from rival Pfizer (PFE), AstraZeneca (AZN) hired advisers with close ties to the Obama administration, who made calls to senior administration officials urging a clamp down on tax inversions, said The Wall Street Journal, citing people familiar with the previously undisclosed calls. Reference Link
07:22 EDTBAYRYBayer unit aims to invest $1B before FY16 in U.S., Reuters says
Subscribe for More Information
06:14 EDTIRWDIronwood downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information
05:37 EDTBAYRYRegeneron submits application for Eylea injection in Japan for macular edema
Subscribe for More Information
September 3, 2014
12:19 EDTSHPGOptions with increasing implied volatility
Subscribe for More Information
11:30 EDTPFEPfizer has conference call hosted by Bernstein
Subscribe for More Information
September 2, 2014
09:41 EDTCELGActive equity options trading on open
Subscribe for More Information
08:21 EDTAMGNAmgen submitts MAA to EMA for evolocumab
Subscribe for More Information
08:20 EDTAMGNAmgen submits application to EMA for talimogene laherparepvec
Subscribe for More Information
08:19 EDTCELGCelgene GED301 drug has positive risk/reward ratio in near-term, says Bernstein
Bernstein believes that the upcoming trial of Celgene's GED0301 drug for Crohn's disease has very little risk in the near-term, while the presentation of results of a study of the drug next month should be positive for the stock. The firm thinks that the drug could emerge as a popular combination partner for other systemic drugs in patients who continue to have disease symptoms. Bernstein is more cautious about the drug's outlook starting in 2016 but keeps a $103 price target and Outperform rating on the stock.
08:07 EDTBAYRYBoston Scientific closed agreement to acquire Interventional business of Bayer
Boston Scientific (BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer (BAYRY). The addition of the Bayer Interventional strong commercial organization and innovative technologies supports the Boston Scientific strategy to provide a comprehensive portfolio of solutions to treat peripheral vascular disease. The transaction includes the leading AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which are used in endovascular procedures to remove blood clots from blocked arteries and veins, and the JetStream Atherectomy System, used in an innovative and fast-growing therapy to remove plaque and thrombi from diseased arteries.
08:01 EDTAMGNAmgen price target raised to $153 from $140 at Leerink
Subscribe for More Information
07:12 EDTBMYCredit Suisse names its Top U.S. Pharmaceutical picks for 2H
Subscribe for More Information
07:10 EDTBMYAlder Biopharmaceuticals regains worldwide rights to clazakizumab
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use